SPEN and neoplasm: Moreover, patients showing parallel progression (CRC-474 and CRC-477) exclusively showed resistance in all primary tumour disseminating subclones, comprising APC, TP53, CREBBP, LEF1 (MIM: 153245), SPEN (MIM: 613484), and MAP2K4 driver mutations.